Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Nova Ltd (NVMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Nova Ltd — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Nova Ltd trades at $329.39 (market cap $10.89B). The key difference: Nova Ltd is far larger — about 11.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Nova Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Nova Ltd for 6 Days on average.
| MRVI | NVMI | |
|---|---|---|
Market Cap | $972.90M | $10.89B |
Volume | 4,325,710 | 416,153 |
Sector | Health | Technology |
52-Week High | $9.00 | $605.65 |
52-Week Low | $2.83 | $275.78 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $1.08B | $10.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
NVMI trades at $342.37, up 0.58% on the day, with a bearish technical signal driven by moving averages but supported by strong fundamentals including a 28.84% net income margin and three consecutive quarterly earnings beats. The stock is positioned near its pivot point of $344, with immediate support at $336. Revenue growth is projected to increase from $881 million in 2025 to $937 million in 2026, though net cash flow turned negative in 2026.
The outlook remains positive given the 85.7% analyst buy rating and a consensus price target of $556.50, implying significant upside. Key risks include high valuation multiples like a P/E of 42.64 and negative cash flow trends, but the company's tool-of-record status in AI chip packaging provides a durable growth catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Nova Ltd
Nova provides metrology solutions for semiconductor manufacturing. Its systems measure material and process characteristics to help chipmakers control production across advanced nodes and packaging.
Read more on NVMI →
